Clinical features of coronavirus disease 2019 complicated with probable sporadic Creutzfeldt-Jakob disease(report of one case)
10.3969/j.issn.1004-1648.2025.01.012
- VernacularTitle:新型冠状病毒病合并散发性克-雅病的临床特征(附1例报告)
- Author:
Lijuan HAN
1
;
Yun XU
1
;
Xin ZHANG
1
Author Information
1. 210008 南京大学医学院附属鼓楼医院神经内科
- Publication Type:Journal Article
- Keywords:
soradic Creutzfeldt-Jakob disease;
coronavirus disease 2019;
visual impairment;
rapidly progressive dementia;
ataxia
- From:
Journal of Clinical Neurology
2025;38(1):52-57
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical features of coronavirus disease 2019(COVID-19)complicated with probable sporadic Creutzfeldt-Jakob disease(sCJD).Methods The clinical data of one patient with COVID-19 complicated with probable sCJD were retrospectively analyzed,and the relevant literatures were reviewed.Results The patient was a 66-year-old male,onset with visual impairment and ataxia,and gradually developed rapid progressive cognitive impairment,mental and behavioral abnormalities,pyramidal tract signs and other manifestations.Serum anti-myelin oligodendrocyte glycoprotein immunoglobulin G antibody was positive(1∶32),CSF Tau protein was significantly increased,14-3-3 protein was positive,and cranial MRI had more than 2 cortical involvement,which was diagnosed as likely sCJD.The patient was infected with COVID-19 about 1 month after the onset of the disease,and the condition gradually worsened.Eleven cases of sCJD complicated with COVID-19 were reviewed form the literature.Combined with this case,the median age of 12 patients was 70 years old,and 66.67％were male.The total Tau level in CSF was significantly increased in 75％of sCJD patients,and positive pathogenic prion protein was detected by real-time quaking-induced conversion method in 66.67％of patients.83.33％of patients received early glucocorticoid or intravenous gamma globulin treatment,with no significant effect.72.7％of the patients died within 2-5 months of onset,and 18.2％of the patients developed shallow coma within 1-2 months of onset.Conclusions COVID-19 has the potential to accelerate the development of sCJD.Elevated level of protein Tau is a promising target for differentiating sCJD contaminant with COVID-19 and autoimmue encephalitis.
